4//SEC Filing
Michael Robert A. 4
Accession 0001415889-24-004416
CIK 0001551152other
Filed
Feb 19, 7:00 PM ET
Accepted
Feb 20, 5:15 PM ET
Size
17.9 KB
Accession
0001415889-24-004416
Insider Transaction Report
Form 4
AbbVie Inc.ABBV
Michael Robert A.
DirectorCHIEF EXECUTIVE OFFICER
Transactions
- Award
Common Stock, $0.01 par value
2024-02-15+49,565→ 148,210 total - Award
Common Stock, $0.01 par value
2024-02-15+13,216→ 161,426 total - Award
Common Stock, $0.01 par value
2024-02-15+10,146→ 171,572 total - Award
Common Stock, $0.01 par value
2024-02-15+12,030→ 183,602 total - Award
Option (Right to Buy)
2024-02-15+59,888→ 59,888 totalExercise: $0.00From: 2025-02-15Exp: 2034-02-14→ Common Stock (59,888 underlying)
Footnotes (5)
- [F1]Represents shares of AbbVie common stock issued under a performance share award granted to the reporting person on February 18, 2021. The award is subject to performance-vesting restrictions based on earnings per share and relative total shareholder return. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2024.
- [F2]Represents shares of AbbVie common stock issued under a performance-vesting restricted stock unit award granted to the reporting person on February 18, 2021. The award is subject to performance-vesting restrictions based on a relative return on invested capital measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2024.
- [F3]Represents shares of AbbVie common stock issued under a performance-vesting restricted stock unit award granted to the reporting person on February 17, 2022. The award is subject to performance-vesting restrictions based on a relative return on invested capital measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2024.
- [F4]Represents shares of AbbVie common stock issued under a performance-vesting restricted stock unit award granted to the reporting person on February 16, 2023. The award is subject to performance-vesting restrictions based on a relative return on invested capital measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2024.
- [F5]Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 19,963 on February 15, 2025, 19,963 on February 15, 2026, and 19,962 on February 15, 2027.
Documents
Issuer
AbbVie Inc.
CIK 0001551152
Entity typeother
Related Parties
1- filerCIK 0001699914
Filing Metadata
- Form type
- 4
- Filed
- Feb 19, 7:00 PM ET
- Accepted
- Feb 20, 5:15 PM ET
- Size
- 17.9 KB